(SPAC) Special Purpose Acquisition Investigation: PRDS,
SAN DIEGO, July 10, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection...
Source: globenewswire.com
📰 Fs Development Corp News
Fs Development Corp News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Fs Development Corp. Real-time updates on events, politics, business and more.
(SPAC) Special Purpose Acquisition Investigation: GMTX,
SAN DIEGO, March 29, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection...
New York United States Jim Baker Johnson Fistel Fs Development Corp Advent Technologies Holdings Inc
Source: globenewswire.com
(SPAC) Johnson Fistel, LLP is Investigating Numerous
SAN DIEGO, March 04, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of law in connection...
Source: globenewswire.com
Irenic Capital Management, LP: Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review
Despite Months of Private Engagement From Irenic and Presumably Other Investors, Chairman CEO Rick E. Winningham and Theravance's Board Refuse to Act in Shareholders' Best Interests Notes Theravance's
Source: finanznachrichten.de
RM LAW Announces Investigation of Pardes Biosciences, Inc.
/PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of Pardes Biosciences, Inc. ("Pardes" or the "Company") (NASDAQ:...
Source: prnewswire.com
Pardes Biosciences nets $199 million in COVID-19 pill race
The Carlsbad startup is in early clinical trials for an experimental antiviral oral treatment for COVID-19, akin to Tamiflu for influenza.
Heidi Henson Pardes Biosciences Pardes Bioscience Ridgeback Biotherapeutics Rylee Arnold Jim Tananbaum
Source: latimes.com
Newly public Pardes Bio aims to show its Covid-19 pill can offer edge over Pfizer's
Pardes Biosciences’ experimental oral antiviral for treating and preventing Covid-19 infection addresses the same target as Pfizer’s authorized pill Paxlovid, but with a potential dosing advantage. The Pardes pill is in Phase 1 testing, and the biotech joined the public markets this week after completing a SPAC merger that infuses the company with $274 million.
Pardes Biosciences Gilead Sciences Melinda Gates Foundation Assembly Pharmaceuticals Fs Development Corp T Rowe Price Associates
Source: medcitynews.com
Carlsbad's Pardes Biosciences nets $199M in SPAC deal to keep pace in the COVID-19 pill race
Startup is in early clinical trials for an experimental antiviral oral treatment for COVID-19, akin to Tamiflu for influenza.
Heidi Henson Pardes Biosciences Pardes Bioscience Rylee Arnold Jim Tananbaum Purpose Acquisition Company
Source: sandiegouniontribune.com
Pardes to go public, says Covid-19 antiviral pill does not need booster
Pardes Biosciences on Tuesday said early human testing shows that its experimental Covid-19 antiviral pill works as a standalone treatment and announced plans to go public by merging with a special purpose acquisition company. If the drug, called PBI-0451, proves effective in later-stage testing, it could have an advantage over similar pills that need to be taken with a
Source: deccanherald.com
Pardes to go public, says Covid-19 antiviral pill does not need booster
Pardes Biosciences on Tuesday said early human testing shows that its experimental COVID 19 antiviral pill works as a standalone treatment and announc...
Source: thepeninsulaqatar.com